Purpose-built, high-precision MRD testing
Ultrasensitive ctDNA detection
Learn how we support clinicians and biopharma in our mission by providing ultrasensitive MRD testing for informed clinical management and therapeutic development.

High precision
Exceptional sensitivity
Neoadjuvant response
Measure ctDNA in the neoadjuvant setting to assess treatment response.
Residual disease detection
Treatment response assessment
Recurrence surveillance
Purpose built
The Haystack MRD difference
A track record of Innovation and leadership
Haystack MRD is the product of more than 20 years of pioneering work in liquid biopsy technologies and is purpose-built for ultrasensitive ctDNA detection.
Guide treatment with Confident MRD results
Prioritized patient access with The power of Quest
End-to-end reliability powered by Quest Diagnostics credentialed staff, labs, logistics, service, reporting, test menu, and technology. Haystack MRD is seamlessly integrated into Quest Diagnostics advanced oncology testing for easy access and reliability.
Purpose built
The Haystack MRD difference
MRD testing demands high-sensitivity ctDNA detection. Haystack MRD is a tumor-informed, next-generation MRD test that detects ultralow levels of ctDNA to uncover residual disease after definitive surgery.
- Innovation and leadership
-
A track record of Innovation and leadership
Haystack MRD is the product of more than 20 years of pioneering work in liquid biopsy technologies and is purpose-built for ultrasensitive ctDNA detection.Haystack MRD has been developed on the foundational work of cancer genomics pioneers, whose discoveries have transformed clinical practice for cancer patients. - Confident MRD results
-
Confident MRD results
Haystack MRD’s technology enables ultrasensitive ctDNA testing with the ability to detect 95% of cases at 0.0006% tumor fraction. With an exceptionally low limit of detection, you can uncover the insights you need to help make confident treatment decisions. -
- The power of Quest
-
Prioritized patient access The power of Quest
End-to-end reliability powered by Quest Diagnostics credentialed staff, labs, logistics, service, reporting, test menu, and technology.Screening
Hereditary genetic risk and colorectal clinical solutionsDiagnosis
Subspecialized pathology solutionsPrognosis
Molecular testingTreatment selection
Solid tumor NGS, heme NGS, hereditary cancer NGSMonitoring
Therapy impact and routine testing post-treatment

A track record of Innovation and leadership
Confident MRD results

Prioritized patient access The power of Quest
Screening
Diagnosis
Prognosis
Treatment selection
Monitoring
Industry upates
Recent news

Learn about Haystack MRD™ at ASCO 2025

Haystack MRD™ by Quest Diagnostics® at SSO 2025
